Efficacy and Safety of PARP inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Clinical Trials

Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths among men in the United States, with an estimated 288,300 new cases and 34,700 deaths in 2023 [1]. Over the last decade, the landscape of treatments has changed significantly with the approval of several agents that improve overall survival in patients with metastatic prostate cancer, including androgen-receptor signaling inhibitors (ARSI) (abiraterone acetate [2], enzalutamide [3], apalutamide [4], and darolutamide [5]), and radioligand therapies (radium-223 [6] and 177Lu-PSMA-617 [7]).
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research